Myriad Genetics (MYGN) Tops Q4 EPS by 6c, Offers Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.06 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $209.8 million versus the consensus estimate of $207.17 million.

GUIDANCE:

Myriad Genetics sees Q1 2026 revenue of $200-203 million, versus the consensus of $211.3 million.

Myriad Genetics sees FY2026 revenue of $860-880 million, versus the consensus of $869.5 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy
• PENN Entertainment (PENN) Reiterated at Market Outperform by Citizens as Relocation Announced